NEW YORK, April 1, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple conferences in April.
Cancer Immunotherapy Conference: Stem Cells and Cancer Immunotherapy
- Date and Time: Friday, April 5, 10:35 AM EDT
- Venue: Washington Post Conference Center, Washington, DC
- Session: Challenges and Solutions for the Commercial Manufacture of Immunomodulatory Cell Products
- Speaker: Robert A. Preti, PhD, President and Chief Scientific Officer of PCT
Second International Vatican Adult Stem Cell Conference: Regenerative Medicine – A Fundamental Shift in Science and Culture
- Dates: Thursday, April 11 to Saturday, April 13
- Venue: Aula Nuova del Sinodo, Vatican City
- Speakers: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem, Robert A. Preti, PhD, President and Chief Scientific Officer of PCT, Jonathan Sackner-Bernstein, M.D., FACC, Vice President of Clinical Development and Regulatory Affairs of NeoStem, and Catherine Vaczy, Esq., Vice President and General Counsel of NeoStem, will all present as part of the conference
CMC Workshop: From Drug Development to Global Supply to Patients
- Date and Time: Wednesday April 17, 8:00 AM EDT
- Venue: Washington Marriott Hotel, Washington, DC
- Session: Advanced-Therapy Medicinal Products (ATMP)
- Speaker: Robert A. Preti, PhD, President and Chief Scientific Officer of PCT
Regen Med and Advanced Therapies Investor Day
- Date and Time: Wednesday April 17, 2:15 PM EDT
- Venue: Harmonie Club, New York, NY
- Speaker: Jonathan Sackner-Bernstein, M.D., FACC, Vice President of Clinical Development and Regulatory Affairs of NeoStem, will give a presentation on Amorcyte
AFUND Small Cap Opportunities Luncheon Symposium
- Date and Time: Monday April 22, 12:00 PM EDT
- Venue: Princeton Club, New York, NY
- Speaker: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem, will give a company presentation
Stem Cell Research & Regenerative Medicine – 10th Stem Cell Summit
- Venue: Hyatt Regency Boston Hotel, Boston, MA
- Session 1 Date and Time: Monday, April 29, 3:30 PM EDT
- Session 1 Title: Commercialization: Bringing Therapeutics to Market
- Session 1 Speaker: Robert A. Preti, PhD, President and Chief Scientific Officer of PCT
- Session 2 Date and Time: Tuesday, April 30, 11:15 AM EDT
- Session 2 Title: Advances in Adult Stem Cells
- Session 2 Speaker: Jonathan Sackner-Bernstein, M.D., FACC, Vice President of Clinical Development and Regulatory Affairs of NeoStem
BIO International Convention – BioProcess Zone
- Date and Time: Tuesday, April 23, 2:00 PM EDT
- Venue: McCormick Convention Center, Chicago, IL
- Session: Leveraging a CMO to optimize the financial and operational efficiency of an emerging cell therapy business
- Speaker: Robert A. Preti, PhD, President and Chief Scientific Officer of PCT
About NeoStem, Inc.
NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization ("CDMO") providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com
Forward-Looking Statements for NeoStem, Inc.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts for cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.